Hennekam Lymphangiectasia–Lymphedema Syndrome 2 (HKLLS2): Comprehensive Disease Characteristics Report

Disease: Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) OMIM: #616006 · MONDO: MONDO:0014217 · Orphanet: ORPHA:2136 (Hennekam syndrome) · ICD-10: Q82.0 (hereditary lymphedema) Causal gene: FAT4 (FAT atypical cadherin 4; HGNC:23109; 4q28.1) · Inheritance: Autosomal recessive Category: Mendelian

Summary

Hennekam lymphangiectasia-lymphedema syndrome 2 (HKLLS2) is an ultra-rare, autosomal recessive generalized lymphatic dysplasia caused by biallelic loss-of-function variants in FAT4, an atypical Fat/Dachsous-family cadherin located at 4q28.1. It is the second genetically defined form of Hennekam syndrome — HKLLS1 is caused by CCBE1 and HKLLS3 by ADAMTS3 — and is allelic to Van Maldergem syndrome (VMS), which arises from FAT4 or DCHS1 mutations and shares a facial gestalt and intellectual disability but generally lacks the lymphedema that defines Hennekam syndrome. The disease was molecularly delineated by Alders and colleagues in 2014 through homozygosity mapping and whole-exome sequencing of the original Hennekam family, in whom no CCBE1 mutation had been found (PMID: 24913602).

Mechanistically, FAT4 acts cell-autonomously in lymphatic endothelial cells (LECs) to establish planar cell polarity (PCP) in response to fluid flow, working with its binding partner Dachsous1 (DCHS1) to drive lymphatic valve and vessel morphogenesis. Loss of FAT4 disrupts LEC polarization, causing defective lymphatic valves and dysfunctional lymphatic drainage; this converges on the same VEGF-C/VEGFR3 prolymphangiogenic axis in which CCBE1 and ADAMTS3 operate (by proteolytically activating pro-VEGF-C). FAT4/DCHS1 signaling additionally regulates Hippo/YAP-dependent cortical neurogenesis, which explains the neurodevelopmental features. The downstream clinical consequences form a characteristic tetrad: congenital/generalized lymphedema, intestinal lymphangiectasia with protein-losing enteropathy (PLE), facial dysmorphism, and variable (mild-to-moderate) intellectual disability, with additional multisystem involvement (chylous effusions, pericardial effusion, hearing loss, hypogammaglobulinemia).

There is no curative therapy. Management is supportive and multidisciplinary: complete decongestive therapy for lymphedema, high-protein/low-fat/medium-chain-triglyceride nutrition and albumin/immunoglobulin support for intestinal lymphangiectasia and PLE, drainage/management of effusions, and symptomatic care of dysmorphic, cognitive, and sensory features. Diagnosis is established by molecular genetic testing (exome/genome sequencing or a primary-lymphedema gene panel including CCBE1, FAT4, ADAMTS3) within the standardized primary lymphatic dysplasia diagnostic pathway, supported by imaging (lymphoscintigraphy, MR lymphangiography), intestinal biopsy showing lymphangiectasia, and laboratory evidence of hypoalbuminemia and hypogammaglobulinemia. Prevention relies on genetic counseling with the option of prenatal or preimplantation genetic testing in at-risk families.

Evidence base: this is an ultra-rare disorder (~50 Hennekam-syndrome cases reported worldwide; the FAT4 subtype a minority). Nearly all information derives from individual patient case reports/small cohorts (human clinical), model-organism studies (mouse, Drosophila), and in vitro biochemistry — not from large aggregated registries or EHR datasets. Where data are absent, this is stated explicitly.

Key Findings

Finding 1 — HKLLS2 is caused by biallelic loss-of-function FAT4 variants (autosomal recessive; OMIM #616006)

The genetic basis of HKLLS2 was established by Alders et al. (2014). Using homozygosity mapping combined with whole-exome sequencing in the original Hennekam family — in whom CCBE1 mutations had been excluded — they identified a homozygous FAT4 mutation, then confirmed the gene by targeted analysis of a CCBE1-negative cohort:

"We used homozygosity mapping and whole-exome sequencing in the original HS family with multiple affected individuals in whom no CCBE1 mutation had been detected, and identified a homozygous mutation in the FAT4 gene. Subsequent targeted mutation analysis of FAT4 in a cohort of 24 CCBE1 mutation-negative Hennekam syndrome patients identified homozygous or compound heterozygous mutations in four additional families." — PMID: 24913602

The autosomal recessive inheritance and the OMIM identifier #616006 for the FAT4-associated form are corroborated in the ADAMTS3 delineation paper:

"It is an autosomal recessive condition caused by biallelic mutations in CCBE1 ... (HKLLS1; OMIM 235510) or FAT4 (HKLLS2; OMIM 616006)." — PMID: 30450763

Reported FAT4 variants are biallelic — homozygous in consanguineous families or compound heterozygous — and predominantly loss-of-function: missense, nonsense, frameshift, and splice-site changes. A 2026 report described a novel biallelic intron-14 splice variant (c.12479+3A>G) causing HKLLS2, with aberrant splicing confirmed by RT-PCR of patient fibroblasts (PMID: 41992670). FAT4 is allelic to Van Maldergem syndrome, so the same gene produces distinct but overlapping phenotypes depending on variant and modifier context.

Finding 2 — FAT4 controls LEC polarity and lymphatic valve morphogenesis, converging on the VEGF-C/VEGFR3 pathway shared by all Hennekam genes

FAT4 is the molecular linchpin of HKLLS2 pathophysiology. Betterman et al. (2020) demonstrated that FAT4 functions within LECs to sense flow and establish polarity, and that it is a transcriptional target of the lymphatic master regulator GATA2:

"we demonstrate that FAT4 functions in a lymphatic endothelial cell-autonomous manner to control cell polarity in response to flow and is required for lymphatic vessel morphogenesis throughout development" — PMID: 32182215

Pujol et al. (2017) showed that the Dachsous1–Fat4 PCP module directs endothelial cell polarization specifically during lymphatic valve morphogenesis, and directly linked valve defects to the lymphedema seen in FAT4-Hennekam syndrome:

"Our data demonstrate that Fat4 and Dachsous1 are critical regulators of valve morphogenesis. This study highlights that valve defects may contribute to lymphedema in Hennekam syndrome caused by Fat4 mutations." — PMID: 28705793

Crucially, all three principal Hennekam genes act in a shared prolymphangiogenic pathway. CCBE1 (a matrix protein) and ADAMTS3 (a protease) proteolytically cleave and activate pro-VEGF-C, enabling VEGFR3 signaling, while FAT4 governs the endothelial polarity required to build functional vessels and valves:

"encoding a matrix protein and protease, respectively, that regulate activity of the key prolymphangiogenic VEGF-C/VEGFR3 signaling axis by facilitating the proteolytic cleavage and activation of VEGF-C. The fact that FAT4, CCBE1, and ADAMTS3 mutations underlie Hennekam syndrome suggested that all 3 genes might function in a common pathway" — PMID: 32182215

The VEGF-C activation mechanism is further supported by biochemical work showing that an ADAMTS3–CCBE1 complex is required to convert VEGF-C (but not VEGF-D) into an active VEGFR3 ligand (PMID: 27159393) and that the two domains of CCBE1 promote VEGFR3 signaling by distinct mechanisms (PMID: 28687807). PROX1 (master LEC identity factor) and VEGFR-3 form the developmental backbone of this system (PMID: 29842991).

Finding 3 — Core clinical phenotype: congenital lymphedema, intestinal lymphangiectasia/PLE, facial dysmorphism, and variable intellectual disability

Ivanovski, Alders, and Hennekam (2018) reviewed all reported FAT4 patients (VMS n=11, HS n=40), delineating the shared and distinguishing features of the two allelic conditions:

"Both conditions are characterized by a typical facial gestalt and mild to moderate intellectual disability, but differ in the occurrence of neonatal hypotonia and feeding problems, hearing loss, tracheal anomalies, and osteopenia in VMS, and lymphedema in HS." — PMID: 29681106

Individual case reports document the full clinical spectrum: generalized/peripheral lymphedema, facial anomalies (hypertelorism, flat nasal bridge, flat facial profile), camptodactyly, hypotonia, and duodenal lymphangiectasia with hypoalbuminemia and hypogammaglobulinemia (PMID: 25616299, PMID: 41992670). The intestinal lymphangiectasia (a form of Waldmann disease) drives protein-losing enteropathy as a downstream consequence:

"Primary intestinal lymphangiectasia (WD) is a consequence of HS, which ultimately results in PLE and worsening interstitial lymph buildup." — PMID: 38028107

Finding 4 — Model organisms recapitulate PCP, kidney, neural, and lymphatic phenotypes

Fat4-null mice and Drosophila fat mutants provide strong cross-species mechanistic support. In mouse (NCBI Taxon 10090; gene Fat4), Saburi et al. (2008) established the PCP role:

"Loss of Fat4 disrupts oriented cell divisions and tubule elongation during kidney development, leading to cystic kidney disease. Fat4 genetically interacts with the PCP genes Vangl2 and Fjx1 in cyst formation." — PMID: 18604206

Cappello et al. (2013) recapitulated the neurodevelopmental component and linked FAT4/DCHS1 to Hippo/YAP signaling:

"Reducing the expression of Dchs1 or Fat4 within mouse embryonic neuroepithelium increased progenitor cell numbers and reduced their differentiation into neurons, resulting in the heterotopic accumulation of cells below the neuronal layers in the neocortex, reminiscent of the human phenotype. These effects were countered by concurrent knockdown of Yap" — PMID: 24056717

The lymphatic-specific phenotype is captured by Fat4-deficient mice with defective valve morphogenesis and endothelial polarity (PMID: 28705793, PMID: 32182215). In Drosophila (Taxon 7227; ortholog fat), neuron-specific fat knockdown provides a model relevant to the intellectual-disability/neuronal features:

"Neuron-specific knockdown of fat shortened the life span and induced the defect in locomotive abilities of adult flies... Both VMS and HS show mental retardation and neuronal defects. We therefore consider that these two rare human diseases could possibly be caused by the defect in FAT4 function in neuronal cells." — PMID: 28488382

Finding 5 — Management is supportive; no curative therapy exists

There is no disease-modifying or curative treatment for HKLLS2. Lee et al. (2018) summarize the rehabilitative approach:

"There is no curative therapy at this time, but rehabilitative treatments including complete decongestive therapy for edema control appeared to be beneficial." — PMID: 29560340

Management is therefore symptomatic and multidisciplinary: complete decongestive therapy (manual lymphatic drainage, compression, exercise, skin care) for lymphedema; nutritional management of intestinal lymphangiectasia/PLE with a high-protein, low-fat, medium-chain-triglyceride diet plus correction of hypoalbuminemia and hypogammaglobulinemia; drainage/management of chylous and pericardial effusions (PMID: 26686525); and symptomatic care for facial dysmorphism, intellectual disability, hearing loss, and cardiac anomalies.

Finding 6 — Gene/protein identifiers, variant spectrum, and epidemiology

FAT4 (FAT atypical cadherin 4) identifiers: HGNC:23109, NCBI Gene 79633, Ensembl ENSG00000196159, UniProt Q6V0I7, cytoband 4q28.1. The gene encodes a very large (~4,981-aa) single-pass atypical cadherin — the vertebrate ortholog of Drosophila Fat — with 34 extracellular cadherin repeats, EGF-like domains, and laminin-G domains:

"The FAT4 gene encodes a large protein with extracellular cadherin repeats, EGF-like domains and Laminin G-like domains." — PMID: 28488382

Disease identifiers: OMIM #616006; MONDO:0014217; Orphanet ORPHA:2136 (Hennekam syndrome); ICD-10 Q82.0. Within Hennekam syndrome overall, CCBE1 accounts for approximately 25% of cases, with FAT4 and ADAMTS3 explaining additional subsets:

"It can be caused by mutations in CCBE1 which are found in approximately 25 % of cases." — PMID: 24913602

Hennekam syndrome is ultra-rare (Orphanet prevalence <1/1,000,000). As of 2023, roughly 50 cases had been reported worldwide:

"As far as we know, this is the 51st case of HS worldwide and the first one in an African American." — PMID: 38028107

Finding 7 — Diagnosis relies on molecular genetic testing within the primary lymphatic dysplasia workup

Diagnosis integrates family history, clinical signs (generalized lymphedema, dysmorphism, developmental delay), pathology, and genetic testing:

"Diagnosis of the disease depends on the familial history, clinical signs, pathological findings and genetic tests." — PMID: 25616299

Molecular confirmation is achieved by exome/genome sequencing or a primary-lymphedema gene panel including CCBE1, FAT4, and ADAMTS3, detecting biallelic variants; splice variants can be functionally confirmed by RT-PCR of patient fibroblasts (PMID: 41992670). Gene selection is guided by the standardized Connell/Gordon/Mansour classification and diagnostic algorithm for primary lymphatic dysplasia:

"In 2010, we introduced a new classification and diagnostic pathway as a clinical and research tool. This algorithm has been used to delineate specific primary lymphoedema phenotypes, facilitating the discovery of new causative genes." — PMID: 23621851

Supportive tests include duodenal/intestinal biopsy showing lymphangiectasia, low serum total protein/albumin and low immunoglobulins (PLE), and imaging (Doppler ultrasound, MRI, CT, lymphoscintigraphy/MR lymphangiography) demonstrating lymphatic anomalies and effusions.

Finding 8 — Anatomy, congenital onset, chronic progressive course, and variable prognosis

The primary defect resides in the lymphatic vasculature (UBERON:0001473 lymphatic vessel; lymphatic valve) and affects lymphatic endothelial cells (CL:0002138). Multisystem involvement is documented: limbs (peripheral/generalized lymphedema), intestine/duodenum (intestinal lymphangiectasia, UBERON:0000160), face/craniofacial skeleton (dysmorphism), brain/cerebral cortex (intellectual disability, periventricular heterotopia via FAT4/DCHS1; PMID: 24056717), heart/pericardium (pericardial effusion, cardiac defects; PMID: 38028107), ear (hearing loss), and serous cavities (chylous ascites, pleural/pericardial effusions):

"whose clinical phenotype also includes protein losing enteropathy, painful relapsing chylous ascites, and hypogammaglobulinemia" — PMID: 26686525

Onset is congenital/neonatal, with edema often present at birth or in infancy:

"presented to our center with generalized edema, ascites, and hypoalbuminemia" — PMID: 25925991

The course is chronic and lifelong — generally progressive/fluctuating with episodic effusions and increased infection (cellulitis) risk. Prognosis is variable and is largely determined by the severity of intestinal lymphangiectasia/PLE and of serous effusions (PMID: 38028107, PMID: 29560340).

Section-by-Section Report

1. Disease Information

HKLLS2 is an autosomal recessive generalized lymphatic dysplasia — one of the genetically defined forms of Hennekam syndrome — characterized by congenital lymphedema, intestinal lymphangiectasia, facial dysmorphism, and variable intellectual disability. It is a Mendelian, disease-level (not EHR/individual-patient-derived) entity delineated from aggregated case reports and cohort reviews.

Key identifiers: OMIM #616006; MONDO:0014217; Orphanet ORPHA:2136 (Hennekam syndrome); ICD-10 Q82.0 (hereditary lymphedema); MeSH — "Lymphangiectasis, Intestinal" / "Lymphedema" (no dedicated MeSH term for the FAT4 subtype).

Synonyms / alternative names: Hennekam syndrome type 2; Hennekam lymphangiectasia-lymphedema syndrome 2; lymphedema-lymphangiectasia-mental retardation syndrome (FAT4-related); generalized lymphatic dysplasia, FAT4-type. Allelic disorder: Van Maldergem syndrome 2 (VMS2, FAT4).

2. Etiology

Causal factor: purely genetic — biallelic loss-of-function variants in FAT4 (PMID: 24913602). No environmental or infectious cause.

Genetic risk factors: the disease-defining variants are the causal factor; there are no established susceptibility loci beyond the biallelic FAT4 genotype. Consanguinity is a major contributor because homozygous variants predominate in affected families. A candidate fourth gene, FBXL7, has been proposed on the basis of a homozygous single-exon deletion in a Hennekam-like patient lacking CCBE1/FAT4/ADAMTS3 variants; FBXL7 interacts with Fat in Drosophila, suggesting a shared pathway (PMID: 31633297) — a potential modifier/allelic locus rather than a confirmed HKLLS2 gene.

Environmental / protective factors: none established. No protective alleles or lifestyle factors are known for this monogenic disorder.

Gene–environment interactions: not characterized. Phenotypic variability (expressivity) is likely influenced by modifier genes within the Fat/Dachsous/Hippo network and by the specific residual function of hypomorphic alleles, but this remains inferred rather than demonstrated.

3. Phenotypes

Severity is variable and the course is chronic-progressive/fluctuating. Quality-of-life impact is substantial: chronic lymphedema limits mobility and predisposes to recurrent cellulitis; PLE causes failure to thrive, immunodeficiency, and effusions; intellectual disability affects independent functioning. No disease-specific QoL instrument (EQ-5D/SF-36/PROMIS) data exist for this ultra-rare condition.

4. Genetic / Molecular Information

Causal gene: FAT4 (HGNC:23109; NCBI Gene 79633; Ensembl ENSG00000196159; UniProt Q6V0I7; 4q28.1). Protein: ~4,981-aa single-pass atypical cadherin with 34 extracellular cadherin repeats, EGF-like domains, and laminin-G domains — vertebrate ortholog of Drosophila Fat (PMID: 28488382).

Pathogenic variants: biallelic (homozygous in consanguineous families or compound heterozygous), predominantly loss-of-function — missense, nonsense, frameshift, and splice-site. Example: novel intron-14 biallelic splice variant c.12479+3A>G with RT-PCR-confirmed aberrant splicing (PMID: 41992670). Classification per ACMG/AMP: reported variants range from pathogenic to likely pathogenic; loss-of-function is the consistent functional consequence. These variants are absent or ultra-rare in population databases (gnomAD) in the homozygous state.

Functional consequence: loss of function / reduced FAT4 signaling.

Modifier genes: DCHS1 (FAT4's cognate ligand) and downstream Hippo/YAP effectors; FBXL7 proposed as a pathway member/candidate gene (PMID: 31633297). Epigenetic/chromosomal abnormalities: none specific to HKLLS2; single-exon deletions (e.g., in FBXL7) illustrate that copy-number changes in pathway genes can produce a Hennekam-like phenotype.

5. Environmental Information

Not applicable — HKLLS2 is a monogenic disorder with no established environmental, lifestyle, or infectious contributors. Environmental factors may modulate secondary complications (e.g., skin trauma precipitating cellulitis, dietary fat load exacerbating lymphangiectasia) but are not causal.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic loss-of-function FAT4 variants → loss/reduction of functional FAT4 atypical cadherin protein. (Demonstrated — PMID: 24913602)
2. Loss of FAT4 → disrupted Fat4–Dachsous1 (DCHS1) planar cell polarity signaling at the cell surface. (Demonstrated in mouse/fly — PMID: 28705793, PMID: 18604206)
3. In lymphatic endothelial cells, disrupted PCP → failure of flow-responsive LEC polarization (FAT4 is a GATA2 transcriptional target). (Demonstrated — PMID: 32182215)
4. Failed LEC polarization → defective lymphatic valve and vessel morphogenesis, converging on the VEGF-C/VEGFR3 axis that CCBE1/ADAMTS3 also feed. (Demonstrated — PMID: 28705793, PMID: 32182215)
5. Defective valves/vessels → impaired lymphatic drainage and lymph stasis → congenital generalized lymphedema. (Inferred from valve defects → clinical lymphedema)
6. Branch — intestine: dysfunctional intestinal lymphatics → intestinal lymphangiectasia → leakage of lymph/protein into gut lumen → protein-losing enteropathy → hypoalbuminemia + hypogammaglobulinemia → worsening interstitial edema, effusions, immunodeficiency. (Demonstrated as downstream consequence — PMID: 38028107)
7. Branch — brain: loss of FAT4/DCHS1 → increased neural progenitor proliferation, reduced neuronal differentiation via Hippo/YAP → cortical malformation/periventricular heterotopia → intellectual disability. (Demonstrated in mouse — PMID: 24056717)
8. Branch — craniofacial/other: disrupted PCP-dependent tissue morphogenesis → facial dysmorphism, skeletal and sensory (hearing) anomalies. (Inferred)

   FAT4 biallelic LOF variants
             │
   ↓ loss of FAT4 atypical cadherin
             │
   ↓ disrupted FAT4–DCHS1 PCP + Hippo/YAP signaling
        ┌────────────┬───────────────┬─────────────┐
        ↓            ↓               ↓             ↓
   LEC polarity   neural progenitor  craniofacial   (kidney/PCP
   failure        overproliferation  morphogenesis   in models)
        ↓            ↓               ↓
   valve/vessel   ↓ neuronal diff.   facial
   defect         (YAP-dependent)    dysmorphism
        ↓            ↓
   lymph stasis   cortical heterotopia
   ┌──────┴──────┐   ↓
   ↓             ↓  intellectual disability
generalized   intestinal
lymphedema    lymphangiectasia
                  ↓
              protein-losing enteropathy
                  ↓
          hypoalbuminemia, hypogammaglobulinemia,
          chylous effusions, immunodeficiency

Molecular pathways: Fat/Dachsous planar cell polarity; Hippo/YAP; VEGF-C/VEGFR3 (FLT4) prolymphangiogenic signaling. Cellular processes: endothelial cell polarization, oriented cell division, valve morphogenesis, neural progenitor differentiation. Protein dysfunction: loss of function of a giant atypical cadherin (impaired cell–cell adhesion/signaling). Immune involvement: secondary hypogammaglobulinemia from PLE (loss of immunoglobulins), not primary autoimmunity. GO term suggestions: GO:0001945 (lymph vessel development), GO:0001938 (positive regulation of endothelial cell proliferation), GO:0001736 (establishment of planar polarity), GO:0035329 (Hippo signaling). Cell types (CL): CL:0002138 (endothelial cell of lymphatic vessel); neural progenitor cells. CHEBI: medium-chain triglycerides (therapeutic entity class).

7. Anatomical Structures Affected

• Primary organ/system: lymphatic vasculature (UBERON:0001473 lymphatic vessel; lymphatic valve) — cardiovascular/lymphatic system.
• Secondary organs: intestine/duodenum (UBERON:0000160; intestinal lymphangiectasia, PLE); brain/cerebral cortex (UBERON:0000956; intellectual disability, heterotopia); face/craniofacial skeleton (dysmorphism); heart/pericardium (effusions, cardiac defects); ear (hearing loss); serous cavities (peritoneal, pleural, pericardial — chylous effusions).
• Tissue/cell level: lymphatic endothelium (CL:0002138); neuroepithelial progenitors; connective/soft tissue (edema).
• Subcellular: plasma membrane cadherin signaling complex (GO:0005886 plasma membrane); cell junctions.
• Lateralization: lymphedema is typically generalized/bilateral rather than unilateral.

8. Temporal Development

• Onset: congenital/neonatal; edema frequently present at birth or in early infancy (PMID: 25925991, PMID: 41992670).
• Progression: chronic, lifelong; generally progressive with fluctuating/episodic exacerbations (effusions, cellulitis). Intestinal lymphangiectasia/PLE may worsen over time.
• Course pattern: chronic progressive with episodic complications; no spontaneous remission of the underlying lymphatic defect (symptomatic control possible with therapy).
• Critical periods: perinatal/early infancy for edema and PLE onset; early childhood for developmental/cognitive support.

9. Inheritance and Population

• Epidemiology: ultra-rare. Hennekam syndrome overall has ~50 reported cases worldwide (as of 2023; PMID: 38028107); Orphanet prevalence <1/1,000,000. CCBE1 accounts for ~25% of Hennekam cases; FAT4 explains a further genetically heterogeneous subset (PMID: 24913602).
• Inheritance: autosomal recessive; biallelic (homozygous or compound heterozygous) FAT4 variants.
• Penetrance/expressivity: presumed high penetrance for biallelic LOF; expressivity is variable (severity of lymphedema, PLE, and cognitive impairment differ between families). Van Maldergem vs Hennekam presentations from the same gene illustrate marked phenotypic variability.
• Consanguinity: important — homozygous variants are frequently found in consanguineous families.
• Founder effects / carrier frequency: none established; carrier frequency is not quantified given rarity.
• Sex ratio: no sex predilection (autosomal recessive; M≈F).

10. Diagnostics

• Clinical/laboratory: low serum total protein and albumin (hypoalbuminemia), low immunoglobulins (hypogammaglobulinemia) from PLE; fecal alpha-1-antitrypsin (PLE marker, inferred).
• Imaging: Doppler ultrasound, MRI, CT; lymphoscintigraphy and MR lymphangiography demonstrating lymphatic anomalies, lymphangiomas, and effusions.
• Pathology/biopsy: duodenal/intestinal biopsy showing dilated lacteals/lymphangiectasia (PMID: 25616299).
• Genetic testing (confirmatory): whole-exome or whole-genome sequencing, or a primary-lymphedema/lymphatic-dysplasia gene panel including CCBE1, FAT4, ADAMTS3; detection of biallelic variants. Splice variants confirmed functionally by RT-PCR of patient fibroblasts (PMID: 41992670). Chromosomal microarray can detect exon/CNV deletions in pathway genes (PMID: 31633297).
• Diagnostic framework: the Connell/Gordon/Mansour classification and diagnostic algorithm for primary lymphatic dysplasia guides workup and gene selection (PMID: 23621851).
• Differential diagnosis: Hennekam syndrome types 1 (CCBE1) and 3 (ADAMTS3); Van Maldergem syndrome (allelic FAT4/DCHS1); other primary lymphedemas (Milroy disease/FLT4, lymphedema-distichiasis/FOXC2); Noonan syndrome with lymphatic involvement; primary intestinal lymphangiectasia (Waldmann disease) without syndromic features.

11. Outcome / Prognosis

Prognosis is variable and depends chiefly on the severity of intestinal lymphangiectasia/PLE and of serous effusions. Chronic PLE causes failure to thrive, immunodeficiency (recurrent infections), and refractory effusions; severe lymphedema predisposes to recurrent cellulitis. No formal survival statistics exist given rarity; life expectancy can be reduced in severe cases but many patients survive into adulthood with supportive care. Morbidity is dominated by chronic lymphedema, PLE-related nutritional/immunologic compromise, and intellectual disability. Prognostic factors: severity/extent of lymphatic dysplasia, degree of hypoalbuminemia/hypogammaglobulinemia, and presence of cardiac/pericardial involvement (PMID: 38028107, PMID: 29560340).

12. Treatment

No curative therapy exists (PMID: 29560340). Management is supportive:

• Lymphedema: complete decongestive therapy — manual lymphatic drainage, multilayer compression, exercise, meticulous skin care (NCIT: Complete Decongestive Therapy / Physical Therapy).
• Intestinal lymphangiectasia / PLE: high-protein, low-fat, medium-chain-triglyceride (MCT) diet (NCIT: Dietary Intervention); parenteral albumin and immunoglobulin replacement as needed; consideration of octreotide in refractory PLE (inferred from general lymphangiectasia management).
• Effusions: drainage of chylous ascites/pleural/pericardial effusions; dietary fat restriction (PMID: 26686525).
• Surgical/interventional: treatment of localized lymphatic malformations; symptomatic surgery for effusions.
• Multidisciplinary symptomatic care: developmental/educational support for intellectual disability, audiology for hearing loss, cardiology for cardiac anomalies, genetics/genetic counseling.
• Experimental/targeted: no approved targeted therapy; the shared VEGF-C/VEGFR3 axis is a plausible future therapeutic node but is unproven in HKLLS2. No pharmacogenomic considerations established.

13. Prevention

• Primary prevention: not possible (genetic); genetic counseling of at-risk (especially consanguineous) families.
• Secondary/tertiary prevention: early detection and management of PLE, effusions, and cellulitis to prevent complications; compression therapy to slow lymphedema progression.
• Genetic screening: carrier testing of relatives once the familial FAT4 variants are known; prenatal diagnosis and preimplantation genetic testing available for known biallelic variants.
• Counseling: recurrence risk 25% for offspring of two carriers; cascade testing recommended.

14. Other Species / Natural Disease

• Taxonomy/orthologs: mouse Fat4 (NCBI Taxon 10090), Drosophila fat (Taxon 7227). FAT4 is the vertebrate ortholog of Drosophila Fat.
• Natural disease: no well-characterized naturally occurring FAT4-lymphedema disorder in companion animals or wildlife is documented (OMIA — no established entry for a FAT4-Hennekam animal disease).
• Comparative biology: the Fat/Dachsous/Hippo PCP module is deeply evolutionarily conserved from Drosophila to mammals, and loss-of-function reproduces morphogenetic defects (kidney cysts, neural over-proliferation, lymphatic valve defects) across species.

15. Model Organisms

Model applications: dissecting PCP/Hippo signaling, lymphatic valve development, cortical neurogenesis, and organ morphogenesis. Limitations: no single model fully reproduces the complete human multisystem phenotype (lymphedema + PLE + dysmorphism + cognitive impairment simultaneously); embryonic lethality of full knockouts necessitates conditional/tissue-specific approaches. Resources: MGI (mouse), FlyBase (Drosophila), IMPC/IMSR for allele repositories.

Mechanistic Model / Interpretation

HKLLS2 is best understood as a planar-cell-polarity/Hippo signaling disorder with a dominant lymphatic phenotype. The unifying lesion is loss of the giant atypical cadherin FAT4, which normally partners with Dachsous1 to transmit tissue-level polarity information and to restrain YAP-driven proliferation. In the lymphatic endothelium this polarity signal is required for cells to align to flow and construct competent valves and vessels — so its loss produces lymph stasis and the congenital lymphedema, intestinal lymphangiectasia, and chylous effusions that dominate the clinical picture. In the developing cortex the same signal restrains progenitor proliferation and promotes neuronal differentiation, so its loss yields heterotopia and intellectual disability. Because CCBE1 and ADAMTS3 (the other Hennekam genes) act on the parallel VEGF-C/VEGFR3 activation step required to build lymphatics, mutations in any of the three genes converge on failure of functional lymphatic development, explaining the shared Hennekam phenotype despite distinct molecular entry points. This convergence is the central mechanistic insight of the report and is supported by both human genetics and mouse/fly models.

Evidence Base

Limitations and Knowledge Gaps

1. Small evidence base: ~50 Hennekam cases total worldwide and only a subset are FAT4-positive, so all frequencies are qualitative; no formal penetrance, expressivity, survival, or QoL statistics exist.
2. Genotype–phenotype correlation between HKLLS2 and allelic Van Maldergem syndrome is incompletely understood — why the same gene produces lymphedema in some patients and not others is unresolved.
3. No natural-history or registry data to quantify progression rate or complication incidence.
4. No dedicated animal model reproduces the full multisystem human phenotype simultaneously.
5. Therapeutics: no targeted therapy has been tested; the VEGF-C/VEGFR3 node is a theoretical target only.
6. Modifier genes (DCHS1, FBXL7, Hippo effectors) are hypothesized but not validated as clinical modifiers.
7. Several ontology mappings (specific UBERON/CL/GO terms) are suggested rather than curated for this specific disease.

Proposed Follow-up Experiments / Actions

1. Assemble an international FAT4-HKLLS2 patient registry to quantify phenotype frequencies, penetrance, expressivity, and natural history.
2. Genotype–phenotype study correlating specific FAT4 variant type/location with lymphatic vs neurodevelopmental vs VMS-like presentations.
3. LEC-specific conditional Fat4 mouse with lymphatic-valve and intestinal-lymphatic readouts to model the full HKLLS2 lymphatic phenotype and test VEGF-C/VEGFR3 pathway modulation.
4. Functional validation of candidate genes/modifiers (FBXL7, DCHS1) in the Fat4 pathway using patient fibroblasts/organoids.
5. Evaluate MCT-diet, octreotide, and albumin/Ig-replacement protocols prospectively for PLE control in this population.
6. Curate definitive ontology annotations (HPO frequencies, UBERON, CL, GO, NCIT) for knowledge-base ingestion.

Report compiled from 8 confirmed findings and 23 reviewed papers across 5 investigation iterations. Evidence types: human clinical (case reports, cohort reviews, molecular genetics), model organism (mouse, Drosophila), and in vitro/biochemical (VEGF-C activation studies).